Redefining drug development with precision therapeutics
Redefining drug development with precision therapeutics
Dysruptx is a University of Glasgow born biotechnology company developing a class of precision-guided peptide therapeutic known as 'Dysruptors'. Dysruptors are engineered from the point of discovery to maximise on-target activity while minimising off-target toxicity; addressing a dominant driver of clinical-stage drug failure
Dysruptx is a University of Glasgow born biotechnology company developing a class of precision-guided peptide therapeutic known as 'Dysruptors'. Dysruptors are engineered from the point of discovery to maximise on-target activity while minimising off-target toxicity; addressing a dominant driver of clinical-stage drug failure
Dysruptx is a University of Glasgow born biotechnology company developing a class of precision-guided peptide therapeutic known as 'Dysruptors'. Dysruptors are engineered from the point of discovery to maximise on-target activity while minimising off-target toxicity; addressing a dominant driver of clinical-stage drug failure
01
Naturally engineered with precision
Naturally engineered with precision
Naturally engineered with precision
Naturally engineered with precision
Protein–protein interactions (PPIs) have evolved over millions of years to achieve highly selective partner recognition, ensuring precise and exclusive interactions within complex biological networks
Protein–protein interactions (PPIs) have evolved over millions of years to achieve highly selective partner recognition, ensuring precise and exclusive interactions within complex biological networks
02
Mapping the PPI interface
Mapping the PPI interface
Mapping the PPI interface
Mapping the PPI interface
Dysruptx harnesses the naturally evolved interface of a target PPI, mapping their uniquely selective binding characteristics
Dysruptx harnesses the naturally evolved interface of a target PPI, mapping their uniquely selective binding characteristics
03
Discovering Dysruptors
Discovering Dysruptors
Discovering Dysruptors
Discovering Dysruptors
Applying these insights directly into the drug discovery process enables Dysruptx to develop Dysruptors, a class of macrocyclic peptide engineered to mimic and disrupt disease-driving PPIs with precision
Applying these insights directly into the drug discovery process enables Dysruptx to develop Dysruptors, a class of macrocyclic peptide engineered to mimic and disrupt disease-driving PPIs with precision
04
Discovering Dysruptors
Discovering Dysruptors
Discovering Dysruptors
Discovering Dysruptors
By minimising off-target risk at the earliest stages of discovery, Dysruptors enable a highly targeted approach to treating human disease, minimising the potential for side effects
By minimising off-target risk at the earliest stages of discovery, Dysruptors enable a highly targeted approach to treating human disease, minimising the potential for side effects
A close look at Dysruptors
Tunable pharmacokinetics
Unparalleled Target Selectivity
Potent & Stable
Broad target compatibility
Modality flexibility
Broad target compatibility
Medium macrocycles (1-3 kDa, NCE)
Medium macrocycles (1-3 kDa, NCE)
Patients
Enabling more effective, targeted therapies with reduced risk of off-target side effects — supporting safer and more reliable treatment outcomes.
Pharmaceutical & biotech partners
Reducing a major driver of clinical-stage failure earlier in development — improving efficiency, timelines, and overall risk.
A close look at Dysruptors
Tunable pharmacokinetics
Unparalleled Target Selectivity
Potent & Stable
Broad target compatibility
Modality flexibility
Broad target compatibility
Medium macrocycles (1-3 kDa, NCE)
Medium macrocycles (1-3 kDa, NCE)
Patients
Enabling more effective, targeted therapies with reduced risk of off-target side effects — supporting safer and more reliable treatment outcomes.
Pharmaceutical & biotech partners
Reducing a major driver of clinical-stage failure earlier in development — improving efficiency, timelines, and overall risk.
A close look at Dysruptors
Tunable pharmacokinetics
Unparalleled Target Selectivity
Potent & Stable
Broad target compatibility
Modality flexibility
Broad target compatibility
Medium macrocycles (1-3 kDa, NCE)
Medium macrocycles (1-3 kDa, NCE)
Patients
Enabling more effective, targeted therapies with reduced risk of off-target side effects — supporting safer and more reliable treatment outcomes.
Pharmaceutical & biotech partners
Reducing a major driver of clinical-stage failure earlier in development — improving efficiency, timelines, and overall risk.
We’re developing precision macrocyclic peptide therapeutics designed to treat human disease while reducing off-target toxicity from the earliest stages of discovery.
IT'S FREE
Connect with us
Investors, partners, enquiries
We’re developing precision macrocyclic peptide therapeutics designed to treat human disease while reducing off-target toxicity from the earliest stages of discovery.
IT'S FREE
Connect with us
Investors, partners, enquiries
We’re developing precision macrocyclic peptide therapeutics designed to treat human disease while reducing off-target toxicity from the earliest stages of discovery.
IT'S FREE
Connect with us
Investors, partners, enquiries